New drug cocktail aims to improve kidney transplant success

NCT ID NCT05669001

Completed Disease control Sponsor: ITB-Med LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new combination of drugs—siplizumab, belatacept, and mycophenolic acid—in 76 people who just received a kidney transplant. The goal was to see if this combo is safer and works better than the usual immunosuppression therapy. Researchers measured side effects and kidney function over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siplizumab (TCD601) combined with belatacept and mycophenolic acid
What this could lead to: If successful, this could offer a new way to prevent organ rejection with fewer side effects than current standard treatments.
What could go wrong: This is an early phase 2 trial with only 76 participants, so results may not apply to everyone. The combination therapy could still cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL TRANSPLANTATION

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
Inova Fairfax Hospital Medical Campus

Falls Church, Virginia, 22042, United States
Loyola University Medical Center

Maywood, Illinois, 60153, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Tampa General Hospital

Tampa, Florida, 33606, United States
University of California Davis Medical Center

Sacramento, California, 95817, United States
University of California San Francisco Medical Center

San Francisco, California, 94143, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Virginia Health

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.